Immune to Cancer: The CRI Blog
-
“Cancer Immunotherapy Insights from ASCO” Twitter Chat Recap #CIMchat
CRI hosted a Twitter Chat, moderated by STAT’s Sharon Begley, discussing takeaways from the ASCO19 conference last…
-
ASCO19 Recap: Caring for Every Patient, Learning from Every Patient
ASCO19 highlighted a number of immunotherapy developments, including those relating to long-term survival, introducing immunotherapy earlier, biomarkers,…
-
ASCO19 Day 5 Update: CAR T Cells for Pleural Cancers and More Melanoma News
The final day of ASCO19 covered CAR T cells for pleural cancers and long-term updates on several…
-
ASCO19 Day 4 Update: Kidney Cancer, Liver Cancer, Stomach Cancer, Esophageal Cancer, and Melanoma
The fourth day at ASCO19 highlighted immunotherapy strategies for patients with kidney cancer, liver cancer, stomach cancer,…
-
ASCO19 Day 3 Update: Immunotherapy for Brain Cancer, Ovarian Cancer, Lung Cancer, and Patients with HIV
The third day at ASCO19 highlighted immunotherapy strategies for patients with brain cancer, ovarian cancer, lung cancer,…
-
ASCO19 Day 2 Update: Biomarkers in Checkpoint Immunotherapy, Targeting Macrophages, and Cellular Immunotherapies
The second day at ASCO19 highlighted biomarkers that may have value in the context of PD-1 checkpoint…
-
ASCO19 Day 1 Update: Lung Cancer, Head and Neck Cancer, and the Cost of Immunotherapy
The opening day at ASCO19 discussed various immunotherapy combinations for head and neck cancer, a bispecific antibody…

Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.